Search results for "Hemolytic anemia"

showing 9 items of 29 documents

Hemolytic uremic syndrome in an infant following Bordetella pertussis infection.

2006

Reported here is the case of a 6-week-old female infant with a severe Bordetella pertussis infection requiring supportive pressure-positive ventilation in the intensive care unit. After being discharged from the intensive care unit, she developed hemolytic anemia, thrombocytopenia and acute renal failure, which suggested a diagnosis of hemolytic uremic syndrome. The clinical outcome was favorable with no renal consequences. This case suggests there may be a direct cause-effect relationship between B. pertussis infection and hemolytic uremic syndrome.

Microbiology (medical)Hemolytic anemiaPediatricsmedicine.medical_specialtyBordetella pertussisWhooping CoughPertussis toxinBordetella pertussislaw.inventionMedical microbiologylawmedicineHumansbiologybusiness.industryInfantGeneral Medicinebiology.organism_classificationmedicine.diseaseIntensive care unitInfectious DiseasesHemolytic-Uremic SyndromeImmunologyParoxysmal coughFemalebusinessKidney disease
researchProduct

Data of safety in a single-center alemtuzumab treated population

2020

Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach.In the manuscript entitled “Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: report from a single Italian center” by di Ioia M. and collaborators, efficacy and safety data of alemtuzumab were evaluated in a real-world MS population. The aim of the article is to describe in detail the unexpected serious adverse events which occurred in this cohort during and after the administr…

Pediatricsmedicine.medical_specialtyPopulationlcsh:Computer applications to medicine. Medical informaticsSingle CenterMultiple sclerosis03 medical and health sciences0302 clinical medicinemedicinelcsh:Science (General)Adverse effecteducationAutoimmune hemolytic anemiaAlemtuzumabSecondary autoimmune disorders030304 developmental biology0303 health scienceseducation.field_of_studyMultidisciplinarybusiness.industryMultiple sclerosismedicine.diseasePancytopeniaAdverse eventsCohortlcsh:R858-859.7AlemtuzumabSettore MED/26 - NeurologiaAutoimmune hemolytic anemiaSafetybusiness030217 neurology & neurosurgerylcsh:Q1-390medicine.drugNeuroscience
researchProduct

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

2019

Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy caused by a deficiency in the activity of ADAMTS13 leading to the formation of ultra-large multimers of von Willebrand factor (vWF) and abnormal platelet adhesion in the microvasculature. aTTP requires prompt diagnosis and rapid initiation of treatment to limit the risk of negative or fatal outcomes. The clinical diagnosis of aTTP is based on thrombocytopenia and microangiopathic hemolytic anemia and is confirmed by ADAMTS13 <10%. However, the latter confirmation is not always rapidly available, and treatment is typically initiated based on the clinical diagno…

Pediatricsmedicine.medical_specialtybusiness.industryImmunologyEcchymosisThrombotic thrombocytopenic purpuraCell BiologyHematologyMicroangiopathic hemolytic anemiamedicine.diseaseBiochemistryADAMTS13medicineMedical historyCaplacizumabmedicine.symptomMegaloblastic anemiabusinessAdverse effectBlood
researchProduct

Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura

2017

BACKGROUND Thrombotic thrombocytopenic purpura (TTP) is an acute life-threatening microangiopathy with a tendency of relapse characterized by consumptive thrombocytopenia, microangiopathic hemolytic anemia, and spontaneous von Willebrand factor–induced platelet clumping leading to microthrombi. The brain is frequently affected by microthrombi leading to neurologic abnormalities of varying severity. STUDY DESIGN AND METHODS The aim of this observational cohort study was to investigate the prevalence of depression and cognitive deficits in 104 patients having survived acute TTP. TTP survivors were repeatedly assessed by means of different standardized questionnaires to evaluate depression (ID…

Pediatricsmedicine.medical_specialtybusiness.industryImmunologyMicroangiopathyThrombotic thrombocytopenic purpuraCognitionHematologyMicroangiopathic hemolytic anemia030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesImmunology and AllergyMedicineEffects of sleep deprivation on cognitive performanceYoung adultbusinessDepression (differential diagnoses)030215 immunologyCohort studyTransfusion
researchProduct

Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations

2013

Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are associated with mutations in genes encoding proteins of complement system (aHUS). We describe two patients with a clinical history of STEC-HUS, who developed end-stage renal disease (ESRD) soon after disease onset. They received a kidney transplant but lost the graft for HUS recurrence, a complication more commonly observed in aHUS. Before planning a second renal transplantation, the two patients underwent genetic screening for aHUS-associat…

Shiga-toxinGraft RejectionMaleDNA Primer030232 urology & nephrologyEscherichia coli InfectionGene mutationurologic and male genital diseasesGastroenterology0302 clinical medicineRecurrenceRisk Factorshemic and lymphatic diseasesImmunology and AllergyPharmacology (medical)gene mutationKidney transplantationEscherichia coli Infections0303 health sciencesKidneymedicine.diagnostic_testShiga-Toxigenic Escherichia coliAntigens CD46Microangiopathic hemolytic anemiaMiddle AgedPrognosisfemale genital diseases and pregnancy complications3. Good healthPedigreemedicine.anatomical_structureComplement Factor IComplement factor I; gene mutation; hemolytic uremic syndrome; kidney transplantation; membrane cofactor protein; Shiga-toxin; Adult; Antigens CD46; Case-Control Studies; Complement Factor I; DNA Primers; Escherichia coli Infections; Female; Genetic Testing; Graft Rejection; Hemolytic-Uremic Syndrome; Heterozygote; Humans; Kidney Failure Chronic; Kidney Transplantation; Male; Middle Aged; Mutation; Pedigree; Prognosis; Recurrence; Risk Factors; Shiga-Toxigenic Escherichia coli; Thrombocytopenia; Young Adult; Transplantation; Immunology and Allergy; Pharmacology (medical)FemaleCase-Control StudieHumanAdultmedicine.medical_specialtyHeterozygotePrognosiComplement factor IMembrane Cofactor Protein03 medical and health sciencesYoung AdultInternal medicinemedicineHumansGenetic Testing030304 developmental biologyGenetic testingDNA PrimersTransplantationbusiness.industryCD46Risk Factormedicine.diseaseKidney TransplantationThrombocytopeniaTransplantationCase-Control StudiesImmunologyHemolytic-Uremic SyndromeMutationhemolytic uremic syndromeKidney Failure ChronicbusinessAmerican Journal of Transplantation
researchProduct

Autoimmune Hemolytic Anemia and Human Immunodeficiency Virus (HIV) Infection

1988

Excerpt To the editor:In patients with human immunodeficiency virus (HIV) infection, normochromic-normocytic anemia is common (1). Only four cases of autoimmune hemolytic anemia have been reported ...

business.industryAnemiahemic and lymphatic diseasesImmunologyInternal MedicineHuman immunodeficiency virus (HIV)MedicineIn patientGeneral MedicineAutoimmune hemolytic anemiabusinessmedicine.disease_causemedicine.diseaseAnnals of Internal Medicine
researchProduct

Glucose 6-phosphate dehydrogenase Palermo R257M: a novel variant associated with chronic non-spherocytic haemolytic anaemia

2010

chemistry.chemical_classificationHemolytic anemiahaemolytic anaemianew DNA mutationEnzyme defectHematologyhereditary genetic defectBiologymedicine.diseaseMicrobiologychemistry.chemical_compoundSettore MED/38 - Pediatria Generale E SpecialisticaEnzymeBiochemistrychemistryenzyme defectmedicineChronic non-spherocytic haemolytic anaemiaGlucose-6-phosphate dehydrogenaseSpherocytic anemiaG6PDBritish Journal of Haematology
researchProduct

Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura.

2021

Introduction Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, and is a medical emergency with fatal outcome if appropriate treatment is not initiated promptly. Areas covered Authors will review the best options currently available to minimize mortality, prevent relapses, and obtain the best clinical response in patients with immune TTP (iTTP). Available bibliography about iTTP treatment has been searched in Library's MEDLINE/PubMed database from January 1990 until April 2021. Expert opinion The general…

medicine.medical_specialtyPurpura Thrombocytopenic IdiopathicThrombotic microangiopathyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industrymedicine.medical_treatmentThrombotic thrombocytopenic purpuraADAMTS13 ProteinHematologyMicroangiopathic hemolytic anemiaDiseasemedicine.diseaseADAMTS13Targeted therapyPharmaceutical Preparationshemic and lymphatic diseasesmedicineHumansRituximabCaplacizumabIntensive care medicinebusinessRituximabmedicine.drugExpert review of hematology
researchProduct

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management

2021

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic end organ injury due to microvascular platelet-rich thrombi. TTP results from a severe deficiency of the specific von Willebrand factor (VWF)-cleaving protease, ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13). ADAMTS13 deficiency is most commonly acquired due to anti-ADAMTS13 autoantibodies. It can also be inherited in the congenital form as a result of biallelic mutations in the ADAMTS13 gene. In adults, the condition is most often immune-mediated (iTTP) whereas congenital TTP (cTT…

medicine.medical_specialtyThrombotic microangiopathyTTPdiagnosisThrombotic thrombocytopenic purpuralcsh:MedicineReview030204 cardiovascular system & hematologycaplacizumabGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorhemic and lymphatic diseasesInternal medicinefollow-upmedicinethrombotic thrombocytopenic purpuratreatmentbiologybusiness.industrylcsh:RGeneral MedicineMicroangiopathic hemolytic anemiamedicine.diseaseADAMTS13ADAMTS13biology.proteinRituximabFresh frozen plasmaCaplacizumabbusiness030215 immunologymedicine.drugJournal of Clinical Medicine
researchProduct